Interaction of the pyridoindole stobadine with alkoxyl and stable free radicals

Substituted pyridoindoles as biological antioxidants: drug design, chemical synthesis, and biological activity

Great effort has been devoted to design and synthesize biologically active and pharmacologically acceptable antioxidants. Although a number of efficient antioxidant compounds have been designed, synthesized, and tested in animals, none of them have demonstrated sufficient efficacy in human clinical trials without undesirable side effects. Thus new pharmacologically applicable antioxidants have been sought for. Substituted pyridoindoles represent a broad spectrum of pharmacologically active substances including highly effective scavengers of reactive oxygen species. The hexahydropyridoindole scaffold represents a valuable lead with a great deal of knowledge on molecular mechanisms of free radical scavenging, on bioavailability and toxicity. Its modification may yield congeners tailored according to specific requirements for antiradical efficacy, lipophilicity, and basicity, meeting the aim of providing a pharmacologically practicable antioxidant drug as exemplified by the novel derivative SMe1EC2.

Evaluation of the Antioxidant Properties of Propofol and its Nitrosoderivative. Comparison with Homologue Substituted Phenols

Propofol (2,6-diisopropylphenol), some substituted phenols (2,6-dimethylphenol and 2,6-ditertbutylphenol) and their 4-nitrosoderivatives have been compared for their scavenging ability towards 1,1-diphenyl-2-picrylhydrazyl and for their inhibitory action on lipid peroxidation. These products were also compared to the classical antioxidants butylated hydroxytoluene and butylated hydroxyanisole. When measuring the reactivity of the various phenolic derivatives with 1,1-diphenyl-2-picrylhydrazyl the following order of effectiveness was observed: butylated hydroxyanisole > propofol > 2,6-dimethylphenol > 2,6-di-tertbutylphenol > butylated hydroxytoluene. In cumene hydroperoxide-dependent microsomal lipid peroxidation, propofol acts as the most effective antioxidant, while butylated hydroxyanisole, 2,6-di-tertbutylphenol and butylated hydroxytoluene exhibit a rather similar effect, although lower than propofol. In the iron/ascorbate-dependent lipid peroxidation propofol, at concentrations higher than 10 microM, exhibits antioxidant properties comparable to those of butylated hydroxytoluene and butylated hydroxyanisole, 2,6-Dimethylphenol is scarcely effective in both lipoperoxidative systems. The antioxidant properties of the various molecules depend on their hydrophobic characteristics and on the steric and electronic effects of their substituents. However, the introduction of the nitroso group in the 4-position almost completely removes the antioxidant properties of the examined compounds. The nitrosation of the aromatic ring of antioxidant molecules and the consequent loss of antioxidant capacity can be considered a condition potentially occurring in vivo since nitric oxide and its derivatives are continuously formed in biological systems.

Pyridoindole antioxidant stobadine protected bovine serum albumin against the hydroxyl radical mediated cross-linking in vitro

On exposure to free radicals generated by the Fenton reaction system of Fe(2+)/EDTA/H(2)O(2)/ascorbate, bovine serum albumin (BSA), used as a model of water-soluble protein, was losing its water solubility depending on the concentration of the chelated iron. The precipitate was found irreversibly insoluble even in concentrated urea. In the soluble fraction, SDS-PAGE analysis proved the presence of dimers and trimers of BSA, accompanied by enhanced bityrosine fluorescence. The pyridoindole antioxidant stobadine inhibited the process of albumin insolubilization in a concentration-dependent manner, the protective effect being more efficient than that of 2-keto-4-methiolbutyric acid (KMBA). Stobadine was, however, less effective than trolox. The inhibitory effect of the antioxidants, expressed as IC(50), correlated well with the reciprocal values of corresponding second order rate constants for scavenging OHz.rad; radicals. The results indicated that the insolubilization of BSA induced by the Fenton system of Fe(2+)/EDTA/H(2)O(2)/ascorbate was caused by OHz.rad; radical mediated cross-linking of the albumin. The model system proved to be suitable for convenient testing of OHz.rad; radical scavenging ability of new antioxidants in a non-lipid environment.

Indole derivatives as neuroprotectants

It seems to be satisfactorily proved that reactive oxygen species (ROS) participate in numerous pathological processes in the nervous system (NS). Compounds able to interfere with the action of ROS might be useful in prevention and treatment of these pathologies. The search is focused on compounds with a suitable spectrum of pharmacological and pharmacokinetic properties, among which indole derivatives are distinct group with great potential to be further developed. The paper presents an overview of indole derived compounds in which protective action has been demonstrated in the NS in situations in which ROS are excessively generated, such as chemically induced oxidative stress, hypoxia/reoxygenation, ischemia/reperfusion. These compounds include indoleamines (melatonin), carbazoles (carvedilol), carbolines (tetrahydrocarbolines, pyrimidoindoles, vinpocetine). Special attention is paid to the gamma-carboline stobadine. A range of effects which seem to be associated with its neuroprotective actions (antioxidant and ROS scavenging effects, capability to pass the hematoencephalic barrier, pharmacokinetic properties, etc.) are considered. A novel compound with pyrimidoindole structure (U-101033E) is mentioned. Attention is drawn also to the neurotoxic potential demonstrated in some carbolines (2-amino-alpha-carboline, halogenated tetrahydro-beta-carboline "TaClo", harmane, norharmane). The indole nucleus seems to be a promising basis for design and synthesis of new derivatives able to protect the NS against oxidative stress in a variety of acute and chronic NS pathologies.

Total antioxidant potential of resinous exudates from Heliotropium species, and a comparison of the ABTS and DPPH methods

Total reactive antioxidant potential (TRAP) of resinous exudates from Heliotropium species was evaluated by measuring the bleaching of stable free radicals. The antioxidant capacity of the resinous exudates in Trolox equivalents, evaluated from the bleaching of ABTS derived radical cations, ranged from 2.0 M (H. huascoense) to 5.2 M (H. stenophyllum), indicating a very high concentration of phenolic compounds. Considerably smaller values were obtained by measuring the bleaching of DPPH radicals. The ratio between the values obtained employing ABTS derived radicals and DPPH, ranged from 37 (H. megalanthum) to 4.5 (H. chenopodiaceum variety typica). The magnitude of the difference can be considered as an indication of the relative reactivity of the antioxidants present in the exudates. Similar ratios were observed when stoichiometric coefficients were evaluated for representative purified flavonoids obtained from the resinous exudates.

Antioxidant and pharmacodynamic effects of pyridoindole stobadine

1. The review summarizes the most important data known so far on chemistry, pharmacodynamics, toxicology and clinics of the investigational agent, pyridoindole stobadine. 2. Stobadine was shown to be able to scavenge hydroxyl, peroxyl and alkoxyl radicals, to quench singlet oxygen, to repair oxidized amino acids and to preserve oxidation of SH groups by one-electron donation. These effects originated from its ability to form a stable nitrogen-centered radical on indole nitrogen. Consequently, it was able to diminish lipid peroxidation and protein impairment under oxidative stress. 3. In various in vitro and in vivo animal models, stobadine was shown to diminish the impairment of the myocardium induced by mechanisms involving reactive oxygen species (e.g., myocardial infarction, hypoxia/ reoxygenation, catecholamine overexposure). 4. The neuroprotective effect of stobadine was demonstrated in a series of in vivo and in vitro models (brain in situ, brain slices, spinal cord, autonomic ganglia, etc.) during ischemia/reperfusion and hypoxia/ reoxygenation or in the presence of chemical systems generating free oxygen radicals, and so forth. Stobadine improved animal survival rate and synaptic transmission recovery, maintained SH tissue level and diminished lipid peroxidation as well as impairment of Ca-sequestering intracellular systems. 5. Oxidation of low-density lipoproteins (LDLs), which plays a major role in the development of atherosclerosis, was decreased by stobadine in vitro. Both lipid and protein (apo B) components of LDL were protected against Cu(2+)-induced oxidation by this agent. 6. Stobadine proved to be an effective protectant in models of free radical pathology in vivo, such as cyclophosphamide-, MNNG- or 60Co-induced mutagenesis and alloxan-induced hyperglycemia. 7. Besides other remarkable pharmacodynamic effects, stobadine exerts antidysrhythmic, local anesthetic, alpha-adrenolytic, antihistaminic, myorelaxant and antiulcerogenic actions. 8. Pharmacokinetic analyses demonstrated that stobadine was readily absorbed from the gastrointestinal tract. Thanks to its balanced lipo-hydrophilic properties, it was distributed over both water and lipid phases in biological tissues. It was shown to easily penetrate the blood-brain barrier. 9. Acute, subchronic and chronic toxicity studies in several animal species, as well as numerous analyses of embryotoxicity, teratogenicity, mutagenicity and genotoxicity, revealed only a negligible toxic potential of this agent. 10. Phase-one clinical study demonstrated safety of the compound. Only slight side effects--namely, a slight hypotension and a slight sedative effect--were observed subsequent to the highest dose used. In phase-two clinical study, the patients with angina pectoris treated for 4 weeks with stobadine showed a significant decrease in the frequency of anginal attacks, in the number of self-administrations of sublingual nitroglycerine and in plasma lipoprotein, cholesterol and triglyceride levels. A slight decrease in systolic and diastolic blood pressure also was observed. 11. It is suggested that stobadine may be considered a contribution to the search for new effective cardio- and neuroprotectants based on antioxidant or free radical scavenging mechanisms of action.

Neuroprotection by the pyridoindole stobadine: a minireview

The minireview summarizes data documenting that pyridoindole stobadine (STB) may protect nervous structures against oxidative stress. This was demonstrated by the impairment of synaptic transmission in hippocampal slices and sympathetic ganglia exposed to hypoxia/reoxygenation (H/R) in vitro as well as by survival of rats and dogs exposed to brain ischemia/reperfusion (I/R) in vivo. The STB effect was linked mostly to its free radical scavenging and antioxidant properties. STB seems to act primarily on phospholipids, thus protecting the integrity and function of somatic membranes in neurons as well as those in subcellular organelles, such as mitochondria and endoplasmic reticulum. STB prevented damage to Ca2+ sequestering systems in endoplasmic reticulum and synaptosomes induced by lipid peroxidation initiators. It was found to diminish changes in NMDA and adrenergic alpha1-receptors evoked in the brain by I/R or H/R. The compound prevented total thiols, participating in tissue antioxidative protection, from decreasing in brain under these conditions. It readily penetrates into both the hydrophilic and the hydrophobic compartments of the CNS. Data were obtained indicating that in I/R, protection of structures such as brain-blood vessels, endothelium, and/or erythrocytes may participate in the STB effect, besides the direct protection of nervous tissue. STB may be characterized as a potential protectant of the CNS in diseases in which oxidative injury may play an important role, for example, stroke, neurotrauma, chronic brain ischemia, or some neurodegenerative diseases. Its molecule could provide a useful model in the further search for novel compounds with even more pertinent pharmacological and pharmacokinetic profiles.